Browse by category

Zepbound (tirzepatide) available in US pharmacies for adults living with obesity

Eli Lilly and Company has announced that Zepbound (tirzepatide) injection is now available in US pharmacies for adults with obesity (with...

Roche poised to enter anti-obesity medication market with agreement to acquire Carmot Therapeutics

Roche is poised to enter the lucrative anti-obesity medication market after entering into a definitive merger agreement to acquire Carmot...

Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide

Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...

Fractyl expands ERASE Task Force to study underlying GLP-1-based pancreatic gene therapy for T2DM

Fractyl Health has expanded an academic-industry scientific partnership charged with advancing research on the role of the gut and...

AstraZeneca enters obesity market with $2b deal for GLP-1 candidate

AstraZeneca has signed an exclusive license agreement with Shanghai-based biotech Eccogene for ECC5004, an early-stage investigational...

Lilly's Mounjaro (tirzepatide) receives UK marketing authorisation for weight management

Eli Lilly and Company has granted marketing authorisation (MA) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for...

FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management

The FDA has approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that...

Endo Tools Therapeutics announces recruitment of first patient in ESTIME clinical trial

The first patient has been enrolled in Endo Tools Therapeutics’ (ETT) ESTIME clinical trial. The trial is evaluating ETT’s endomina...

Biolexis Therapeutics launches Metabolexis to develop novel oral medicines for obesity and T2DM

Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, has launched Metabolexis, a new pipeline company developing...

Viking Therapeutics completes of enrolment in VENTURE Trial for GLP-1/GIP receptor agonist VK2735

Viking Therapeutics has completed patient enrolment in its Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of...

Obesity-related brain changes can be reversed after bariatric surgery

19 minutes ago

Verge Genomics reveals VRG201 as its candidate for long-term weight management and metabolic homeostasis

31 minutes ago

Structure Therapeutics selects oral small molecule amylin receptor agonist ACCG-2671 for obesity treatment

59 minutes ago

Weekly Digest